Neurocrine Biosciences (NBIX) said late Monday its drug INGREZZA, used to treat tardive dyskinesia, a movement disorder, showed a clinically meaningful response in a late-stage trial.

The company said that after 48 weeks of treatment, 94% of patients achieved either symptomatic remission or clinically meaningful improvement in involuntary movements.

A separate analysis found high hepatic risk factors in patients with tardive dyskinesia, the company said, adding that INGREZZA is the only VMAT2 inhibitor approved for use in patients with hepatic impairment.